Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy

Jean Pierre Routy, Mohamed Rachid Boulassel, Bader Yassine-Diab, Charles Nicolette, Don Healey, Renu Jain, Claire Landry, Oleg Yegorov, Irina Tcherepanova, Tamara Monesmith, Lothar Finke, Rafick Pierre Sékaly

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Immunogenicity, manufacturing feasibility, and safety of a novel, autologous dendritic cell (DC)-based immunotherapy (AGS-004) was evaluated in ten human immunodeficiency virus type 1 (HIV-1)-infected adults successfully treated with antiretroviral therapy (ART). Personalized AGS-004 was produced from autologous monocyte-derived DCs electroporated with RNA encoding CD40L and HIV antigens (Gag, Vpr, Rev, and Nef) derived from each subjects' pre-ART plasma. Patients received monthly injections of AGS-004 in combination with ART. AGS-004 was produced within a mean of 6 weeks and yielded 4-12 doses/subject Full or partial HIV-specific proliferative immune responses occurred in 7 of 9 evaluable subjects. Responses were specific for the AGS-004 presented HIV antigens and preferentially targeted CD8+ T cells. Mild adverse events included flu-like symptoms, fatigue, and injection site reactions. No evidence of autoimmunity, changes in viral load, or significant changes in absolute CD4+ and CD8+ T cell counts were observed. This pilot study supports the further clinical investigation of AGS-004.

Original languageEnglish
Pages (from-to)140-147
Number of pages8
JournalClinical Immunology
Volume134
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

HIV Antigens
Dendritic Cells
HIV-1
HIV
RNA
Safety
T-Lymphocytes
CD40 Ligand
Injections
Viral Load
Autoimmunity
Immunotherapy
Fatigue
Monocytes
Therapeutics
Cell Count

Keywords

  • Acquired immunodeficiency syndrome
  • Dendritic cells
  • HIV
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. / Routy, Jean Pierre; Boulassel, Mohamed Rachid; Yassine-Diab, Bader; Nicolette, Charles; Healey, Don; Jain, Renu; Landry, Claire; Yegorov, Oleg; Tcherepanova, Irina; Monesmith, Tamara; Finke, Lothar; Sékaly, Rafick Pierre.

In: Clinical Immunology, Vol. 134, No. 2, 02.2010, p. 140-147.

Research output: Contribution to journalArticle

Routy, JP, Boulassel, MR, Yassine-Diab, B, Nicolette, C, Healey, D, Jain, R, Landry, C, Yegorov, O, Tcherepanova, I, Monesmith, T, Finke, L & Sékaly, RP 2010, 'Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy', Clinical Immunology, vol. 134, no. 2, pp. 140-147. https://doi.org/10.1016/j.clim.2009.09.009
Routy, Jean Pierre ; Boulassel, Mohamed Rachid ; Yassine-Diab, Bader ; Nicolette, Charles ; Healey, Don ; Jain, Renu ; Landry, Claire ; Yegorov, Oleg ; Tcherepanova, Irina ; Monesmith, Tamara ; Finke, Lothar ; Sékaly, Rafick Pierre. / Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. In: Clinical Immunology. 2010 ; Vol. 134, No. 2. pp. 140-147.
@article{0a75d97c17df45d8993710d2c7f5c83c,
title = "Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy",
abstract = "Immunogenicity, manufacturing feasibility, and safety of a novel, autologous dendritic cell (DC)-based immunotherapy (AGS-004) was evaluated in ten human immunodeficiency virus type 1 (HIV-1)-infected adults successfully treated with antiretroviral therapy (ART). Personalized AGS-004 was produced from autologous monocyte-derived DCs electroporated with RNA encoding CD40L and HIV antigens (Gag, Vpr, Rev, and Nef) derived from each subjects' pre-ART plasma. Patients received monthly injections of AGS-004 in combination with ART. AGS-004 was produced within a mean of 6 weeks and yielded 4-12 doses/subject Full or partial HIV-specific proliferative immune responses occurred in 7 of 9 evaluable subjects. Responses were specific for the AGS-004 presented HIV antigens and preferentially targeted CD8+ T cells. Mild adverse events included flu-like symptoms, fatigue, and injection site reactions. No evidence of autoimmunity, changes in viral load, or significant changes in absolute CD4+ and CD8+ T cell counts were observed. This pilot study supports the further clinical investigation of AGS-004.",
keywords = "Acquired immunodeficiency syndrome, Dendritic cells, HIV, Immunotherapy, Vaccine",
author = "Routy, {Jean Pierre} and Boulassel, {Mohamed Rachid} and Bader Yassine-Diab and Charles Nicolette and Don Healey and Renu Jain and Claire Landry and Oleg Yegorov and Irina Tcherepanova and Tamara Monesmith and Lothar Finke and S{\'e}kaly, {Rafick Pierre}",
year = "2010",
month = "2",
doi = "10.1016/j.clim.2009.09.009",
language = "English",
volume = "134",
pages = "140--147",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy

AU - Routy, Jean Pierre

AU - Boulassel, Mohamed Rachid

AU - Yassine-Diab, Bader

AU - Nicolette, Charles

AU - Healey, Don

AU - Jain, Renu

AU - Landry, Claire

AU - Yegorov, Oleg

AU - Tcherepanova, Irina

AU - Monesmith, Tamara

AU - Finke, Lothar

AU - Sékaly, Rafick Pierre

PY - 2010/2

Y1 - 2010/2

N2 - Immunogenicity, manufacturing feasibility, and safety of a novel, autologous dendritic cell (DC)-based immunotherapy (AGS-004) was evaluated in ten human immunodeficiency virus type 1 (HIV-1)-infected adults successfully treated with antiretroviral therapy (ART). Personalized AGS-004 was produced from autologous monocyte-derived DCs electroporated with RNA encoding CD40L and HIV antigens (Gag, Vpr, Rev, and Nef) derived from each subjects' pre-ART plasma. Patients received monthly injections of AGS-004 in combination with ART. AGS-004 was produced within a mean of 6 weeks and yielded 4-12 doses/subject Full or partial HIV-specific proliferative immune responses occurred in 7 of 9 evaluable subjects. Responses were specific for the AGS-004 presented HIV antigens and preferentially targeted CD8+ T cells. Mild adverse events included flu-like symptoms, fatigue, and injection site reactions. No evidence of autoimmunity, changes in viral load, or significant changes in absolute CD4+ and CD8+ T cell counts were observed. This pilot study supports the further clinical investigation of AGS-004.

AB - Immunogenicity, manufacturing feasibility, and safety of a novel, autologous dendritic cell (DC)-based immunotherapy (AGS-004) was evaluated in ten human immunodeficiency virus type 1 (HIV-1)-infected adults successfully treated with antiretroviral therapy (ART). Personalized AGS-004 was produced from autologous monocyte-derived DCs electroporated with RNA encoding CD40L and HIV antigens (Gag, Vpr, Rev, and Nef) derived from each subjects' pre-ART plasma. Patients received monthly injections of AGS-004 in combination with ART. AGS-004 was produced within a mean of 6 weeks and yielded 4-12 doses/subject Full or partial HIV-specific proliferative immune responses occurred in 7 of 9 evaluable subjects. Responses were specific for the AGS-004 presented HIV antigens and preferentially targeted CD8+ T cells. Mild adverse events included flu-like symptoms, fatigue, and injection site reactions. No evidence of autoimmunity, changes in viral load, or significant changes in absolute CD4+ and CD8+ T cell counts were observed. This pilot study supports the further clinical investigation of AGS-004.

KW - Acquired immunodeficiency syndrome

KW - Dendritic cells

KW - HIV

KW - Immunotherapy

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=73549125003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73549125003&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2009.09.009

DO - 10.1016/j.clim.2009.09.009

M3 - Article

C2 - 19889582

AN - SCOPUS:73549125003

VL - 134

SP - 140

EP - 147

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -